News Related to Progressive Supranuclear Palsy

Related coverage linked through entity extraction aliases.

Arvinas Reports Phase 1 Data Showing ARV-102 Achieves Over 50% LRRK2 Degradation in Parkinson's

Mar 19, 2026

Arvinas announced phase 1 results for ARV-102, a PROTAC degrader that achieved more than 50% LRRK2 degradation in cerebrospinal fluid of Parkinson's patients after 28 days, with no serious adverse events reported.

Study Identifies Distinct Molecular Subtypes of Progressive Supranuclear Palsy

Mar 14, 2026

Researchers at the University of Toronto have discovered that progressive supranuclear palsy has distinct molecular subtypes based on tau protein distribution, opening pathways for precision medicine approaches to treat this fatal neurodegenerative disease.